Esomark Capsule 20mg (Esomeprazole Magnesium Trihydrate)

Adult dosage

1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for another 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurrent symptoms is not recommended for patients at high risk of developing gastric or duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2 inhibitor) use - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting longer than 4 weeks have not been conducted. 4) Patients requiring continued nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into two doses. 6) Maintenance therapy following initiation of prevention of recurrent bleeding due to gastric or duodenal ulcers by intravenous injection Administer 40 mg once daily for 4 weeks following initiation of prevention of recurrent bleeding due to gastric or duodenal ulcers by intravenous injection. 4. Renal impairment No dose adjustment is necessary. Since there is limited experience with administration to patients with severe renal impairment, use with caution. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients No dose adjustment is necessary.

Children's dosage

Adolescents 12 years of age and older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for another 4 weeks. Adolescents 12 years of age and older - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Adolescents 12 years of age and older - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. Adolescents 12 years of age and older - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurrent symptoms is not recommended for patients at high risk of developing gastric or duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Children under 12 years of age - There is no experience with administration of this medicine to children under 12 years of age.

This medication should not be used in certain patients. Patients who are allergic to this drug or its components or have had hypersensitivity reactions should not take it. Care should be taken when using it in conjunction with certain antibiotics or medications, particularly penicillins and macrolide antibiotics. It is also not safe for use in pregnant or breastfeeding women. Different adverse reactions may occur while taking this medication, so caution is necessary. Headaches, abdominal pain, diarrhea, nausea, and dizziness are frequently reported symptoms, while more serious side effects such as blood abnormalities, liver dysfunction, skin rashes, and myalgia can occur infrequently. Especially with long-term use, electrolyte imbalances such as hypomagnesemia may occur, requiring regular monitoring. Because this medication suppresses gastric acid secretion and lowers gastric acidity, the risk of gastrointestinal infections may slightly increase. Furthermore, long-term use may increase the risk of fractures, so caution is advised for patients with osteoporosis. This medication may interact with other medications, so if you are taking other drugs, you must inform your doctor or pharmacist. Because data on its safety during pregnancy is limited, pregnant patients should consult their doctor before taking it. In cases of overdose, there is no specific antidote, so appropriate treatment should be received depending on the symptoms, and observation may be necessary in a hospital if needed. Finally, this medication should be kept out of the reach of children, and care should be taken not to transfer it to other containers, as doing so can affect the quality.

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, dysgeusia, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal bloating, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, hyperhidrosis, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, loss of appetite, apathy, increased appetite, confusion, exacerbation of depression, hypertonicity, sensory impairment, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disturbance, tremor, visual field loss, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, abnormal olfaction, taste loss, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urination frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, skeletal muscle lysis, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric fundic polyps, hypocalcemia, hypokalemia, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis

This medication should be stored in a tightly closed container to protect it from air and moisture and kept at room temperature between 1 and 30 degrees Celsius. This storage method helps maintain the drug's effectiveness and prevents degradation.

Appearance

Hard gelatin capsule with light green upper and yellowish lower, containing white or gray granules

Package unit

28 capsules/bottle